

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: JAN K. CAERS, et al.

Examiner: ANDERSON, Catharine L.

Serial Number: 10/621,054

Art Unit: 3761

Filed: July 15, 2003

Confirmation No.: 8812

For: DEVICE TO ASSIST
HYPERHYDROSIS THERAPY

Irvine, California

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant's provide with regard to the patent application entitled DEVICE TO ASSIST HYPERHYDROSIS THERAPY, filed herewith one copy of a documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

/CLAUDE L. NASSIF/

Date: December 15, 2006

Claude L. Nassif, Ph.D., Reg. No. 52,061

Address all inquires and correspondence to:

Claude L. Nassif, Ph.D.
Allergan, Inc., Legal Department
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714 246 6458
Fax: 714 246 4249

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17595 (BOT)	SERIAL NO.: 10/621,054
APPLICANT CAERS, J. et al.	TITLE: DEVICE TO ASSIST HYPERHYDROSIS THERAPY
FILING DATE: July 15, 2003	GROUP 3761

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	2005-0148935	07JUL2005	DIMITROVA et al.	604	116	29DEC2003
	AB	4,580,561	08APR1986	WILLIAMSON	128	303B	
	AC	4,736,526	12APR1988	HSIA	33	565	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Bigalke, Hans et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> ; <u>Brain Res</u> ; 1985; 360: pp 381-24
	CB	Bigalke, H. et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord</i> ; <u>Naunyn Schmiedeberg's Arch Pharmacol</u> ; 1981; 316; pp 244-51
	CC	Binz, Thomas et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> ; <u>J Biochem</u> ; (Tokyo) 1990 Jun 5; 265(16); pp 9153-8
	CD	Boyd, R.S. et al., <i>The insulin secreting B-cell line, HIT-15, contains SNAP-25 which is a target for botulinum neurotoxin-A</i> ; <u>Mov. Disorders</u> ; 1995; May; 10(3); 376
	CE	Bushara, K.; <i>Botulinum toxin and rhinorrhea</i> ; <u>Otolaryngol Head Neck Surg</u> ; 1996; 114(3); 507
	CF	Ferrari, David M. et al., <i>The protein disulphide-isomerase family: unravelling a string of folds</i> ; <u>Biochem J</u> ; 1999 (339) pp 1-10
	CG	Grimalt, R. et al.; <i>Multi-injection plate for Botulinum toxin application in the treatment of axillary hyperhidrosis</i> ; <u>Dermatol Surg</u> ; 2001, Jun; 27(6); 543-544
	CH	Habermann; E.; <i>I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord</i> ; <u>Naunyn-Schmiedeberg's Arch Pharmacol</u> ; 1974; 281; 47-56
	CI	Habermann, E., <i>Inhibition by tetanus and botulinum A toxin of the release of {3H}noradrenaline and {3H}GABA from rat brain homogenate</i> ; <u>Experientia</u> ; 1988, Mar 15; 44(3) pp 224-6
	CJ	Habermann, E. et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain</i> ; <u>J Neurochem</u> ; Vol 51, No 2 1988; pp 522-7

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17595 (BOT)		SERIAL NO.: 10/621,054
APPLICANT	CAERS, J. et al.	TITLE: DEVICE TO ASSIST HYPERHYDROSIS THERAPY
FILING DATE:	July 15, 2003	GROUP 3761

	CK	Jankovic, Joseph et al., <u>Therapy with Botulinum Toxin</u> ; Marcel Dekker, Inc.; pp 5
	CL	Marjama-Lyons, Jill et al., <i>Tremor-Predominant Parkinson's Disease</i> ; <u>Drugs & Aging</u> ; 2000; April 16 (4) pp273-278
	CM	Moyer, E. et al.; <i>Botulinum Toxin Type B: Experimental and Clinical Experience</i> , pp 71-85 (chapter 6) of <u>Therapy With Botulinum Toxin</u> , edited by Jankovic, J. et al.; Marcel Dekker, Inc. 1994
	CN	Naumann, Markus et al., <i>Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions</i> ; <u>European Journal of Neurology</u> ; 1999, Vol 6 (suppl 4) pp S111-5
	CO	Naumann, M.; <i>Botulinum toxin type A in the treatment of focal hyperhidrosis</i> ; <u>J. Cutaneous Laser Therapy</u> , 2001;3(1); 42-43
	CP	Pearce, Bruce et al., <i>Pharmacologic Characterization of Botulinum toxin for Basic Science and Medicine</i> ; <u>Toxicon</u> ; 1997; 35 (9); pp 1373-412 at 1393
	CQ	Sanchez-Prieto, Jose et al., <i>Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes</i> ; <u>Eur J Biochem</u> ; 1987 Jun; 165 (3); pp 675-81
	CR	Schantz, Edward J. et al., <i>Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine</i> ; <u>Microbiol Review</u> ; 1992 Mar; 56 (1); pp 80-99
	CS	Singh; <i>Critical Aspects of Bacterial Protein Toxins</i> ; pp63-84 (chapter 4) of <u>Natural Toxins II</u> , edited by B.R. Singh et al., Plenum Press, New York 1996
	CT	Sloop, Richard R. et al., <i>Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use</i> ; <u>Neurology</u> ; 1997, Jan; 48 (1); pp 249-53
	CU	Weigand et al.; <i>I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection</i> ; <u>Naunyn-Schmiedeberg's Arch Pharmacol</u> ; 1976, 292; 161-165

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.